In short
TBPN Podcast Episode Summary
Episode Information
- Podcast Title: TBPN (Technology Brothers Podcast Network)
- Episode Title: Nvidia Restarts China Sales, Vibe Coding Backlash, Peptide Craze | Diet TBPN
- Description: A recap of the key discussions from today’s TBPN episode, focusing on major tech news, including Nvidia's chip sales in China, backlash against vibe coding, and the peptide craze.
---
Key Discussions
Nvidia's China Sales Resumption
- Nvidia Announcement:
- Nvidia is restarting production of AI chips for sale in China.
- Jensen Wang confirms the company's supply chains are now ready after previously mixed signals.
- Historical Context:
- Chips were banned from being sold to China in 2022 under the Chips Act.
- The U.S. government aimed to strengthen its economy by restricting technology sales to China.
- Implications of Selling Chips:
- Selling chips to China could decrease the risks associated with a potential Taiwan invasion.
- The U.S. economy benefits from maintaining a chip supply, especially given the ongoing global chip shortage projected to last until at least 2030.
- Risks and Benefits:
- Arguments exist on both sides regarding the benefits of keeping China dependent on U.S. technology versus the risks of enabling a potentially aggressive China.
- There is ongoing debate over the strategic impact of chip sales on global security and the economy.
Vibe Coding and Apple's Crackdown
- Vibe Coding Apps:
- These applications help users create apps without extensive coding knowledge.
- Apple is clamping down on vibe coding apps due to violation of App Store rules regarding running code that alters app functionalities.
- Developer Perspectives:
- Developers express concerns regarding Apple's restrictions impacting their ability to innovate and expand app offerings.
- The discussion suggests a tension between Apple’s control over its ecosystem and the growth of independent app development.
Peptide Craze and Pharmaceutical Insights
- Introduction to Peptides:
- Peptides are small proteins with very short half-lives and have been around as pharmaceuticals since the 1950s.
- There is a growing obsession with peptides in the wellness and fitness communities.
- Risks and Effectiveness:
- Discussion highlights the importance of understanding pharmacokinetics (how drugs travel in the body) for evaluating peptide effectiveness.
- Warnings are raised about the dangers of unapproved research chemicals and the importance of relying on FDA-approved drugs.
- Expert Opinion:
- Martin Shkreli emphasizes the rigorous testing and validation required for pharmaceutical efficacy and expresses skepticism towards many peptide products popular in wellness circles.
Economic Implications of AI on Private Credit
- Private Credit Markets:
- The conversation touches on the rise of private credit markets as a parallel banking system.
- Concerns are raised about the implications of AI on private credit defaults and their potential to lead to economic crises.
- Future Outlook:
- Despite risks, there are suggestions that AI could lead to productivity gains that offset losses in certain economic sectors.
Key Takeaways
- The landscape of AI technology and chip manufacturing continues to evolve, with significant geopolitical implications.
- Tensions between tech companies and regulatory frameworks are apparent, particularly in the context of app development and AI.
- The conversation surrounding health and wellness, particularly around peptides, highlights the need for informed choices and skepticism regarding unregulated products.
- The future of finance, especially concerning private credit, is intertwined with technological advancements and market dynamics.
---
Conclusion The TBPN podcast continues to be a rich source of insights into technology and its multifaceted impact on society and the economy. This episode highlighted critical developments in the tech sector, regulatory challenges faced by developers, and the ongoing discourse around health innovations.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Chapters
Tap a time to open that second in VONVIDIA Restarts Sales in China
0:45 to 3:00
Discussion on NVIDIA's decision to restart production of AI chips for China and the implications.
“Back in 2022, after the Chips Act, which if you want to read up more on it, we've interviewed Chris Miller, the author of Chip War.”
Impact of the Chips Act
3:00 to 4:50
Exploration of the Chips Act and its effects on American chip manufacturing and the economy.
“Global conflicts have grown significantly since then.”
Military Risks and Chip Dependence
4:50 to 7:00
Analyzing the military implications of chip manufacturing and China's reliance on TSMC.
“So we're going to, so like, we can't afford to scale.”
Economic Arguments for Selling Chips
7:00 to 9:35
Debate on the economic rationale behind selling chips to China and its potential benefits.
“approval to ship small amounts of H200 projects products to China to date we have not generated any revenue from those sales.”
NVIDIA's Chip Export Controversy
9:35 to 12:15
Overview of NVIDIA's complicated relationship with chip exports to China and recent developments.
“On a long enough timeline, they will all come to X.”
Apple's Crackdown on Vibe Coding
12:15 to 14:02
Discussion on Apple's restrictions on vibe coding apps and their implications for developers.
“Then Replit ranks number two when you search for Vibecode, because it says Replit, Vibecode apps.”
Introduction to New Simulator
14:02 to 14:50
Discussion about a new simulator and its fun, impactful design.
“And this one we're putting a little bit more effort into.”
Apple's Software Review Challenges
14:50 to 15:46
Exploration of Apple's review policy and sharing limitations for app developers.
“But Test Flight is still like, it's certainly not designed for.”
iOS App Frustrations
15:46 to 17:10
Discussion on issues with the iOS phone and messaging app functionalities.
“Yeah, John finally came around because the phone app is like, you're like, okay, I'm going to hit this button.”
Understanding Peptides
17:10 to 18:55
Introduction to peptides, their history, and pharmacological significance.
“Peptides have extremely short half-lives, often on the order of seconds or minutes.”
Show all 19 chapters
Pharmacokinetics Explained
18:55 to 20:17
Deep dive into pharmacokinetics and the importance of drug testing and development.
“Without a double blind placebo controlled study, there is often nothing to talk about.”
Critique of Unapproved Drugs
20:17 to 21:53
Discussion on the risks and realities of unapproved pharmaceuticals and drug trials.
“chemical shops, wildly illegal, I might add, I would just ship people alanine or something.”
Upcoming Debate on Peptide Use
21:53 to 22:24
Announcement of a debate regarding the use of peptides and pharmaceutical ethics.
“Max Marchione from Superpower will be coming on Monday at 12 to debate Martin Shkreli, the professor, himself.”
Popular Peptides and Their Risks
22:24 to 23:46
Discussion on popular peptides and the associated health risks.
“which is in stage three clinical trials and looking extremely good, or BPC-157, which has tons of clinical and anecdotal evidence.”
Human Nature and Health Optimization
23:46 to 24:16
Exploration of human behavior regarding health optimization and drug use.
“Yep, it's somewhat basically human nature.”
Impact of Private Credit and AI
24:16 to 28:06
Analysis of the relationship between AI developments and the private credit market.
“There's no amount of money you can pay me.”
The Impact of Federal Involvement
28:06 to 28:28
Discussing the potential consequences of federal involvement in the banking sector.
“So some type of like federal kind of involvement sector could make sense.”
AI and Email Communication Challenges
28:28 to 28:51
Exploring how AI is changing email communication and raising spam concerns.
“You don't want to be compared to a scottling creature.”
The Future of Spam Regulations
28:51 to 29:27
Discussing the need for updated spam regulations in the face of AI advancements.
“Nikita was saying February 11th prediction in less than 90 days.”
Transcript
Automatic transcript. May contain errors.0:00John Coogan:The big news of the day, more news out of NVIDIA GTC, lots of NVIDIA announcements. The stock is up. It's a$4.44 trillion company. That is big. But the big news out of NVIDIA yesterday was that NVIDIA says it's restarting production of AI chips for sale in China specifically. Jensen Wang says the company's supply chain is fired up after months of mixed signals from the Chinese market. We've been tracking this for a long time. Of course, chips were banned first from sale for sale to China in 2022 by Joe Biden under the Chips Act that also unlocked billions of dollars in incentives for American chip manufacturing.
0:38John Coogan:And then the narrative flipped back and forth, back and forth on what are the risks and what are the costs and benefits of actually selling chips to China. Back in 2022, after the Chips Act, which if you want to read up more on it, we've interviewed Chris Miller, the author of Chip War. It's a great book. And the calculus has always been pretty clear. Like on the first pass, the first order of facts, AI is an important technology. America wants an advantage in the AI race, the AI build out. So less chips for China means more chips for America, stronger US economic engine. And massive chip shortage right now.
1:13You see old chips being valued basically more than they were when they launched, which implies there's plenty of demand in America. So you'd want to keep those here.
1:23John Coogan:And plenty of demand at TSMC from American chip makers specifically. I mean, even Apple is sort of getting crowded down there on the 2 nanometer, which I think is better for phones than for GPUs. but they're grappling with what the compute boom, what the AI build-out boom will be for their business. In the past, China's dependence on foreign technology companies has been seen as a key bargaining chip. Why would China invade Taiwan when they need to keep TSMC's manufacturing facilities online? Chip manufacturing is extremely precise. One of these factories isn't gonna withstand a rocket hitting it.
2:01John Coogan:So if there is any sort of broad military action in Taiwan, TSMC probably gets a little bit damaged. I mean, even the tiniest earthquake. They have to track the weather. Yes. Outside of the facility. Exactly. If the weather outside of the facilities is fluctuating at all. It can affect the yield inside. Yeah. Taiwan is famous, or TSMC is famous, where they don't even need, apparently, like a detection system or a push notification to their employees if there's an earthquake. If the employees sense that there's an earthquake, they just get up and go to the factory and start working on things. It's not like they need to like, oh, we need to email all the employees.
2:35John Coogan:The employees just know because that's the level of sensitivity over the TSMC fab. So if you want to keep TSMC producing chips, you can't invade Taiwan. And so by banning the export of chips to China, the cost to China of a Taiwan invasion decreases. And so if China can't access TSMC chips anyway, it's a lot less risky to go to war. And that was always the risk with hardcore chip bans. In 2022, the Russia-Ukraine war was about six months old. Global conflicts have grown significantly since then. Obviously, we've been tracking the Iran war. And America's military is potentially stretched thin, so the risks of a Taiwan conflict are higher than ever.
3:15John Coogan:And so you add to the fact that everyone agrees that we will be in chip-constrained, a chip shortage, through at least 2030. And the need to keep TSMC supplying chips to American companies is extremely important. It's always been difficult to parse the various arguments around selling chips to China because there's an insane amount of money at stake and many, many people whose basically their full-time job is to advocate for a particular position. Yeah, not to mention how much of everyone's retirement accounts Nvidia actually makes up. Holding up the world economy, right? That's the meme. There are good arguments on both sides.
3:45John Coogan:One that keeps getting trotted out is, you know, it's important to keep China dependent on the American AI stack and it's reasonable. the better argument might just be dependent on a functional TSMC fab but there is there are benefits to the CUDA ecosystem and to the the idea that whatever models get built there will be applicable here we'll be able to transfer those that research and development that happens over there very quickly the more the economies are interlinked the less likely there is a conflict so all this underscores the importance of TSMC Arizona Samsung Intel broadly as well as startup fab projects like the terra fab well we're traveling this like long and narrow road but i'm coming around to the idea that selling some chips to china is the best possible move at this particular moment in time it was easy to stick with like the first order logic of just we want the chips because we can use them to power our economy so we should have them even if they are getting chips it's not like the the party is going to say actually the domestic our domestic supply chain is no longer important because we're getting a drip of h200s yes so there's these they're still going to keep the momentum that they have it just wouldn't be wouldn't be like them there's a lot of debate over that because momentum comes from you can take some of the wind out of the sails yes but they can just spend you can slow the momentum potentially that's the argument is that is that by limiting demand you're like there's a local local fab in China that just says, well, a chip maker that says, okay, well, you know, our demand is half as much.
5:24John Coogan:So we're going to, so like, we can't afford to scale. Sure. We have the money, but we don't really need to deliver this because there's no buyer. So you don't get the process level of like execution. You don't get the excellence that comes from actually needing to run the real business. It becomes more of like NASA than SpaceX. That's always the risk with like, you know, you're just throwing government money after it. NVIDIA and the Trump administration have been involved in a complicated tango over the sales of its advanced artificial intelligence chips in China. Last April, the Commerce Department halted exports of the H20 processor Nvidia designed explicitly for the China market.
5:59John Coogan:That was the nerfed H200 that was not supposed to be able to train as advanced of models, but it was reported that the High Flyer team behind DeepSeq sort of figured out how to use those chips effectively. So there was a debate over is the H20 actually just as useful as the H200 or close to it or closer? Well, it's sort of a moot question now because H200 is coming to China, which is the more advanced version, the not nerfed version. So the company's fortunes turned again in December when the US said it would allow Nvidia to sell its H200 processor, a chip that is a generation behind its most powerful series of GPUs as long as the company shared 25 % of its sales with the US government so there's basically an export tariff GPUs or graphics processing units are powerful chips used in training models I think everyone knows this but until Tuesday the status of the B200 or the H200 in China was unclear in Nvidia's most recent earnings report the company said that although it had received approval to ship small amounts of H200 projects products to China to date we have not generated any revenue from those sales.
7:07John Coogan:Fong said that in recent weeks demand signals out of China have strengthened. We have been licensed for many customers in China. We've received purchase orders from many customers and we're in the process of restarting our manufacturing. Our supply chain is getting fired up. In other news, J.R.R. Tolkien used Gen Z brain rot slang over 70 years ago. That's how ahead he was. And the quote maggots jeered that and cigars you're cooked white skins will catch you and eat you they're coming oh he's like using it literally like you that you will be cooked by the some some i don't know villain i suppose so the orcs will cook you if you uh if you fall behind i suppose nvidia's biggest gtc announcement was a 20 billion dollar bet on the same problem that cerebris solved six years ago says andrew feldman the ceo and founder of Cerebrus.
8:00John Coogan:Shots fired. Shots fired indeed. He says their next gen inference chip, not available yet, has 140 times less memory and less memory bandwidth than Cerebrus. To run a single 2 trillion parameter model, you need 2 ,000 Grok chips. On Cerebrus, that's just over 20 wafers. Even paired with GPUs, Grok's max is out at 1 ,000 tokens per second. We run at thousands of tokens per second today and every day in production now. Why? When you connect 2 ,000 chips together, every interconnect has latency, every cable has overhead. It doesn't matter what your memory bandwidth is on paper if you're bottlenecked by the wiring between the thousands of tiny chips.
8:42John Coogan:We solved this with wafer scale, one integrated system, little interconnect tax. Jensen told the world that fast inference is where the value is. He's right. It's why the the world's leading AI companies and hyperscalers are choosing Cerebris. And so he puts up a little graphic of Cerebris versus Rubin plus Grok together on one system. And he is touting 90 times the amount of memory, 90 times the number of chips needed to run a two trillion parameter model. Bubble Boy is having some criticism of GTC because apparently people are getting up and asking questions that are intended to pump bags. He says, GTC has turned into a conference It's less about tech and innovation and more about pumping your bags by getting a Jensen soundbite on some niche supply chain player.
9:27They say LinkedIn is the only social platform where you can post a sloppy reaction poll and it will get tons of engagement. We need to do this. Wow, they're just really throwing shots. I give LinkedIn a chance. On a long enough timeline, they will all come to X. It might take 30, 40 years. They'll make it over to the dive bar eventually. Maybe. I like that Semi-Analysis leans into the particular rough edges of every platform.
9:51John Coogan:I follow them on Instagram and they actually post just hilarious vibe reels and brain rot. It's just like brain rot. Yeah. But often it's... I'm the only one that's liking them. I comment on a lot of the videos. Yeah, I comment too. It's amazing. They are not having broad success, but as far as what Instagram deals like... Well, it's like the fine details of inference max or something. Yeah, yeah, yeah. and then it's like Minecraft parkour over it. Apple cracks down on vibe coding apps. It's over for you, Tyler. Apple's moves come as vibe coding apps help people create apps. Vibe coding apps, not vibe coded apps.
10:27I know it's over for him times two. No, because he doesn't vibe code on a phone. I'm kidding, I'm kidding, I'm kidding.
10:33John Coogan:He doesn't vibe code on a phone. I'm kidding. But let's read this. Apple's move comes as vibe coding apps help people create apps for Apple devices as well as web apps that aren't listed in the app store. Apple has quietly prevented AI vibe coding apps such as Replit and VibeCode, which help people create games and other applications, from releasing updates to their mobile apps on the App Store unless they make modifications. The company confirmed it has told some app developers that the vibe coding capabilities violate longstanding App Store rules that say an app can't run code that changes the way it or other apps function.
11:04Apple's crackdown is happening at a time when vibe coding apps are emerging as a potential threat to the company by helping developers create web apps that aren't listed on its app store, a key source of revenue and profits for Apple. Some of these vibe coding apps also help developers create apps for Apple devices. That ability has likely contributed to the explosion of new apps launching on the app store in recent months, leading to a slowdown in approval process in some cases, developers say. It sounds like you're able to basically generate an app with Replit and then use a preview of it that maybe is functioning a little too much and effectively allowing Replit, the app, to do things that Apple didn't approve of.
11:41John Coogan:If you search VibeCode, you get an ad for Replit as the first response. Replit is number three in DevTools, has 14 ,000 five-star reviews or reviews. Then Vibecode is listed as Vibecode website builder, has 3.3k, pretty solid. It doesn't look like it's charting, but it says learn how to Vibecode, no experience needed, build websites with professional designs. Much more focused, I think, on static content, but there's been a number of these, like, website builders in the App Store for a very long time. Then Replit ranks number two when you search for Vibecode, because it says Replit, Vibecode apps.
12:21John Coogan:Would you download this app, Jordy? I don't know if you can see. That's insane. I don't know if you can see, but it's like - Definitely Vibecoded the App Store preview. It's like a graphic, like an AI image of the GigaChad using the computer. It's very funny. But man, there is so much IP infringement. Love a code. Not from Lovable. Love a code. Build with Vibecode. They're like, I wonder who they're trying to SEO against. Do you remember that company that was doing vibe coding on the iPhone and they would tap your phone and basically airdrop you the app? We talked to them at YC Demo Day last year.
13:01John Coogan:Oh, yeah, yeah. And there's a number of these companies that are trying to be the AI game store, sort of like the meta simulator, like build a simulator and create a harness that's really good at vibe coding a game. It feels like a really valuable category if you can crack it, but you are going to be bumping up against the App Store all the time. You just have to compete with Sam Altman, Dario Amadei. Yeah, maybe. Amjad. I do wonder if there will be some sort of, or I mean Roblox would be like the bigger one, maybe? Or does it come out of Codex and Cloud Code instead? For gaming, I just think Roblox is just gonna continue to be like Roblox is the Roblox of vibe coding.
13:49John Coogan:And yet we did not build our simulators in Roblox. Yeah, but they're not like massive multiplayer games. And we want people to be able to click a link and and use it on their phone immediately. We have a new simulator coming by the way. We're addicted to simulation. We do love simulators. And this one we're putting a little bit more effort into. and John's already addicted. I would say this one is like just actually fun. But we're going for impact. We're going for fun. But, you know, Apple's had this long standing policy around do not, do not like they want to review the software. And so you can't create an app that rewrites its software.
14:31Yeah, I wonder if Apple can do anything to create more like a peer, like a mini, like sort of peer to peer experience. because I remember I was like learning how to build iOS apps when I was like an early teenager. And I was so frustrated that I had built Pong, but I couldn't just like share it with my dad and say like, hey, you can play this. Like it just wasn't, it was. You can do Test Flight, right? Yeah, Test Flight. But Test Flight is still like, it's certainly not designed for.
15:00John Coogan:It's not like a social peer-to-peer experience. Like you still have to opt into the test flight network, do all these jumps. Like for some reason, it is weird that it kicks me out of the Apple ecosystem when I get a test flight. Goldrock says, high key, Tyler could make better Siri and Replit with a$1 ,000 budget. For his last$1 ,000. He's down to his last$1 ,000. That's a good challenge. The question is how much is Apple itself vibe coding? Because the software quality in the apps that I use. Mark Gurman said they're using Claude all the time, right? But to me, I'm saying so far, my experience recently, I've had an issue with the most important application on my phone, which is text messages.
15:45John Coogan:You were complaining about the Photos app. That was just poor design. The phone app has gotten a lot. Yeah, John finally came around because the phone app is like, you're like, okay, I'm going to hit this button. I might be calling this person out of the blue, even though I just want to. And I'm not sure what phone line I'm calling them on. I guess they're designing for a world where people only have one phone number, but I still have a lot of people. This is blowing your mind, Tyler. But back in the day - You're talking about like a home phone? Back in the day, people used to have multiple phone lines, multiple phone numbers.
16:17John Coogan:It's true. I'm so unk. But yes - Like a work phone. Yeah, like a work phone. I mean, when I was at FF, I had two phones, but - Two phones. Two phones, that's right. But a lot of people will have a home phone and a mobile phone. And so that was the thing that you saved in your contact book a long time. And the problem with the new iOS phone app is that I've been calling randomly people on their home phone if I have it saved. So I need to maybe go delete those numbers or put them in a comment field so that it always calls their iPhone. Because I have moved to just calling people on their mobile phones.
16:49We've got to go over to SF with Martin Scrawley.
16:51John Coogan:Yeah, wait. Oh, okay. This is part two. We're just jumping straight into the sequel. We're going straight into part two. Okay, we're going straight into part two. He says, have you ever had the thing that you know a lot about become the current thing? That's happening now with peptides. Holy S-H-I-T. I don't know where to start. Pharma Basics. Most people obsessed with peptides don't know a few things. Peptides as pharmaceuticals have been around since the 1950s. A peptide is just a small protein. Peptides have extremely short half-lives, often on the order of seconds or minutes. So if you're saying you're interested in peptides, you're saying, I'm interested in biopharmaceuticals, but only drugs with very weak...
17:27Pharmacokinetics. Pharmacokinetics. Pharmacokinetics. That's a new word for me. Drugs of which peptides are a subgroup usually have a specified target. This is an electrostatic interaction, usually hydrogen bonding between the atoms of the drug and the atoms of the target, typically, but far from always, the receptor. If you can't tell me what the target is and how the drug is binding to it, you do not have a drug. You have delusion. Next, drugs are rigorously, tested rigorously, not only for safety reasons, Just identifying the pharmacokinetics of a substance, how it travels in the body. Pharmacokinetics.
17:58Pharmacokinetics.
17:58John Coogan:It's a collab. Between pharma and kinetics. They're linking and building. Exactly. It's arguably the most important starting point for any medicine. How is it metabolized? What is its half-life? Without this basic information, you can't even begin to have a medicine. You can start pharmacokinetics in animals and scale to humans, but you also need a therapeutic hypothesis. Yes. This is a thoroughly vetted biological idea considered a priori as to why this medicine just might work. You very rarely discover these after the fact. Determining target engagement requires assays. Assays. Assays. This is going to be a rough one.
18:33John Coogan:This is a rough one. Also, a priori, not a priori. Brutal. A priori assumptions. Exposed. What assay was your drug tested in? What did it show? Direct target engagement is very important to falsify your biological hypothesis. And you can continue, John. Preclinical studies are so manufactured and fraudulent in today's day that I wouldn't rely on them for biological hypotheses unless they are from an incredible lab. We're done a priori, etc. There we go. Clinical reality is far harsher. Without a double blind placebo controlled study, there is often nothing to talk about. If I hear, but I know dozens of people one more time, exclamation point, exclamation point, exclamation point.
19:16John Coogan:Screw the FDA and pharma. Really? Really? coming from Martin Screlly, he is saying, maybe don't screw the FDA and pharma. When most of the SF and elsewhere crowd talks about peptides, they're not thinking, and this is gonna be a hard one for me, octreotide. They're thinking some random stuff that's been thrown in animal models and is not FDA approved. Look, I'm not a softy. If there was a drug that could help me or my family, I'd find a way to get it. But I'm also not stupid and spent 20 years looking at pharmaceuticals. Drug companies like to make money. drug companies love looking at random molecules and putting them in clinical trials.
19:52John Coogan:There are thousands of biopharmaceutical companies that are publicly traded. It is not hard to do a trial, a clinical trial from a university. If your drug has never been tested, there is a reason. The reason is not that you are a biopharmaceutical genius who has found something cool that everyone else missed. The FDA plays an important role. They make sure that whatever is on the label is actually in the drug. That's why prescriptions are important. If I operated one of these research chemical shops, wildly illegal, I might add, I would just ship people alanine or something. No one would have any idea that it wasn't BPCBS or whatever is popular right now.
20:29John Coogan:The other side of the argument. There has to be some unapproved drug out there that's useful to take. Yes, there are plenty. That is how I made a living, says Martin Screlly. But it is not for you world traveler to think about this the things you know do not apply to pharmaceuticals you it's not that you're not smart i'm sure you're smarter than i it just takes practice and time to understand medicine i believe some places will even require you to go to school before you can decide who takes what drug just ask your doctor for a medal medical advice there's a reason you don't do surgery on yourself fly a plane by yourself etc but martin i want to optimize my You could fly a 747.
21:05John Coogan:I could. That is the thing that I take. I agree with a lot of this. We don't need studies to know that you could land a 747. If I needed to. If it was asked of you. Yeah. 100%. But Martin, I want to optimize my health. No, stop it. You're not sick. It's all nonsense. Leave medicine to physicians. You do not know what you are doing. Become a physician if you are that interested or spend a lot of time and money on biopharma. I have zero doubt you'll change your mind. There are no health care professionals that I know of who give an SHIT about these unapproved research chemicals. There are actual dying people in the world.
21:42John Coogan:Duquesne muscular dystrophy, PECAN, Lefora. Go fix those diseases. You'll make someone in their family a lot happier than LARPing that you know about medicine. This has to end. Lots of debate. Yeah, so we are going to be hosting. We have a debate. Max Marchione from Superpower will be coming on Monday at 12 to debate Martin Shkreli, the professor, himself. So we're going to have a little debate. Superpower, I believe, sells these small proteins. And so it'll be an interesting conversation. So Monday at 12 Pacific, we can look forward to the great debate. It says, when people talk about peptides, they mostly mean things like retitrutide, which is in stage three clinical trials and looking extremely good, or BPC-157, which has tons of clinical and anecdotal evidence.
22:37John Coogan:Your critique is just self-aggrandizing fluff that falls apart when you apply it to the actual examples most people are using. So he's saying, look, most people aren't using this stuff that's like crazy far out there. They're just pulling forward things that are actively being worked on by the pharmaceutical. Just another pod, guys. This great post would be even better if you were in a flow state with a low dose of Retta. Martin does not think, he doesn't like BPC-157. He says BPC-157 has no evidence LMAO. Retta Trutide is literally a biopharmaceutical from Eli Lilly. Yeah, I mean, the concern with BPC-157 has always been that it could accelerate cancer growth.
23:17Yes, it stimulates growth. Yes. And so because it hasn't been studied well enough in humans, that is a risk that people, I think, should be aware of.
23:29John Coogan:How much of this is actually because of people's AGI timelines? Is there a real overlap in San Francisco between like, yes, it might give me cancer in 20 years, but I think we will cure cancer in 10. So if it makes me look good in the next five. But I think it's all about people just want some type of edge. They want to alter their state. Yep, it's somewhat basically human nature. Yeah, you can make the same argument for why you should wait though because then in 10 years AGI will create like a super drug that would just instantly make me jacked. Oh, right. Okay. It's like you can do But no one has a decade to wait Yeah, you want to be jacked now because because all things equal if the cancer risk of both scenarios is zero You'd rather be jacked for 45 years as opposed to 40 how much how much would we have five?
Read the full transcript
24:15I pay you a day to not lift anything heavier than a single piece of paper. There's no amount of money you can pay me. There's no amount of money. That's right. Exactly. You can't wait 10 years. Private credit and the AI value reallocation. Starts with a quote. The essence of technology is in a lofty sense ambiguous. Such ambiguity points to the mystery of all revealing, i.e. of truth. Martin Heidegger. A familiar intuition about the emergence of any new technological paradigm is that new methods of engaging with the world create uncertainty. which is most easily interpreted through the lens of perceived negative outcomes.
24:49As private credit markets deteriorate, it's tempting to not only to blame AI for that decline, but also to extrapolate any dislocation to its logical extreme. That is, where rising default expectations among software companies are increasingly framed as early signs of a global systemic crisis. The most convenient analogy is the GFC.
25:09John Coogan:And yesterday, Carried No Interest was giving a little bit of a doomer take around some of these software private equity deals. But he was not ringing alarm bells to the tune of the global financial crisis, correct? He was just saying that some of these deals are underwater. Some of those investment professionals might be needing to join different firms to find different opportunities. Sort of the bull case for special situations, right? Leaving the firm and be like, I didn't really work on it. I was an investor, but I didn't do much investing during 2018 to 2022. I was mostly just sitting there saying, guys, I don't think we should do this deal.
25:47I guess the beauty of private credit is that you have all these different funds that are being deployed, that have been deployed on different time horizons, that have longer time horizons in general, right? And so you can have basically like a rolling collapse versus like a run on the bank where you have like one day where everyone realizes. It's kind of like the worm. Like you were doing the worm yesterday. Kind of like that.
26:21John Coogan:Yeah. That does not seem great. It's like a weight. It's like a title. It's like a title weight. It starts small and it gets bigger and bigger and bigger. This framing is incomplete, says Eric Suford in Mobile Dev Memo. He says, it isolates the destructive effects of AI while ignoring the mechanisms through which those effects propagate and where value ultimately accrues. In this piece, he makes the case that contemporary economic conditions bear no resemblance to those leading up to the global financial crisis of 2008. Any weakening in various categories of the software landscape as a result of AI will not only mostly remain contained there, but will likely lead to economically expansionary productivity gains and efficiencies that offset potentially disproportionately losses in private credit.
27:05John Coogan:That's very exciting. I'm only on my second diet coke. Don't talk to me until I've had my 10th energy drink. This is what the Fed had to say. Private credit has emerged as one of the fastest growing segments of non-bank financial intermediaries, NBFIs. Over the past 15 years or so, reaching a total asset class size of$1.34 trillion in the U.S. alone by the middle of 2024. A report from Morgan Stanley published in October of 2025 estimated the size of the private credit market at the start of 2025 at$3 trillion. Private credit is an asset class that functions as a parallel banking system. Don't call it a shadow banking system.
27:44John Coogan:It's just merely parallel in darkness. Look, I'm going to be concerned. Here's what I'm going to be concerned. And you have leaders at these private credit firms that say, you know, look, private credit's amazing. Yeah. But it's unfair that we're keeping all of these gains private and we need to make them public. Yeah, yeah, yeah. So some type of like federal kind of involvement sector could make sense. It would also be really, really bad if, like, one of the most respected leaders of one of the biggest banks in the world was to compare the industry to, like— Cockroach. Yes, like some really, like, you know, some bug.
28:26John Coogan:That would be a bad thing. You don't want to be compared to a scottling creature. No, no, no. Maybe a soaring eagle instead. There are some soaring eagles in this portfolio of private credit assets. Bill Gurley says, I fear that AI has decimated the traditional email inbox as we know it. Too many personalized slop emails slip through the spam filter. Hope someone builds a better mousetrap. This one is cooked in its current form. Great use of the word cooked. Nikita was saying February 11th prediction in less than 90 days. All channels that we thought were saved from spam and automation will be so flooded that they will no longer be usable in any functional sense.
29:04I message phone calls, Gmail. Email inbox certainly feels that way. Nikita says spam laws will need to be rewritten soon. Machines should be prohibited from communicating with humans unprompted. This will actually make your job just actually just hitting the button. Because, like, no, a machine didn't send that. A human did. The human hit the button. And you're going to have to press a button, like, you know, 10 ,000 times a day if you're BDR sending sales emails.
29:30John Coogan:We'll see you tomorrow. Goodbye. Going flashbang. Fire!
29:38you
From the publisher
Diet TBPN delivers the best of today’s TBPN episode in 30 minutes. TBPN is a live tech talk show hosted by John Coogan and Jordi Hays, streaming weekdays 11–2 PT on X and YouTube, with each episode posted to podcast platforms right after.
Described by The New York Times as “Silicon Valley’s newest obsession,” the show has recently featured Mark Zuckerberg, Sam Altman, Mark Cuban, and Satya Nadella.
TBPN is made possible by:
Ramp - https://Ramp.com
AppLovin - https://axon.ai
Cisco - https://www.cisco.com
Cognition - https://cognition.ai
Console - https://console.com
CrowdStrike - https://crowdstrike.com
ElevenLabs - https://elevenlabs.io
Figma - https://figma.com
Fin - https://fin.ai
Gemini - https://gemini.google.com
Graphite - https://graphite.com
Gusto - https://gusto.com/tbpn
Kalshi - https://kalshi.com
Labelbox - https://labelbox.com
Lambda - https://lambda.ai
Linear - https://linear.app
MongoDB - https://mongodb.com
NYSE - https://nyse.com
Okta - https://www.okta.com
Phantom - https://phantom.com/cash
Plaid - https://plaid.com
Public - https://public.com
Railway - https://railway.com
Restream - https://restream.io
Sentry - https://sentry.io
Shopify - https://shopify.com/tbpn
Turbopuffer - https://turbopuffer.com
Vanta - https://vanta.com
Vibe - https://vibe.co
Follow TBPN:
https://TBPN.com
https://x.com/tbpn
https://open.spotify.com/show/2L6WMqY3GUPCGBD0dX6p00?si=674252d53acf4231
https://podcasts.apple.com/us/podcast/technology-brothers/id1772360235
https://www.youtube.com/@TBPNLive



